Top 50 Biotech Startup Investors in United States
A list of 50 angel investors and VC funds that invest in Biotech startups based in United states. We rank investors based on the number of investments they made in Biotech companies from United states. We update this investor list every month.Top 50 Biotech Startup Investors in United States
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
- Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Vilya — Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases.
- Moleculent — Moleculent is adding a functional layer of biology to pave the way for unparalleled advancements in biological research.
- Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, France, Canada
Portfolio highlights
- Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
- TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- Chemomab — Pioneering Innovative Treatments for Patients with Fibrosis-Related Diseases
- MBX Biosciences — Homepage - MBX Biosciences
- Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- MBX Biosciences — Homepage - MBX Biosciences
- Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.
- Cardurion Pharmaceuticals — A Boston-based cardiovascular biotechnology company developing next-generation therapeutics for the treatment of heart failure and cardiovascular diseases.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Disc Medicine — Disc Medicine is led by an experienced team of scientists and industry experts, and supported by a panel of advisors with a strong track record of discovering and developing new and innovative therapies. Disc Medicine was founded by Atlas Venture and Brian MacDonald, with Novo Ventures and Access Biotechnology joining as additional investors.
- Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
- GRO Biosciences — GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency,stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity. The company, co-founded by Dr. George Church, is located at the Harvard Life Lab, shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
- Health Care, Medical, Medical Device
- Seed, Pre-Seed, Convertible Note
- United States, Argentina, United Kingdom
Portfolio highlights
- Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
- iYOTAH Solutions — iYOTAH Solutions is a transformational SaaS technology company that connects data to help the animal protein industry thrive.
- Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
- LENZ Therapeutics — LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
- Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series A, Series C
- United States, Ireland, Singapore
Portfolio highlights
- Nomad Health — Search travel nurse jobs nationwide. Earn more money, haggle-free. Receive expert support without the pushy tactics of a traditional recruiter.
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Series C
- United States, United Kingdom, China
Portfolio highlights
- Odaseva — Odaseva is the leading enterprise data platform for Salesforce. Industry leaders rely on Odaseva to keep data protected, compliant, and agile.
- RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
- Canary Technologies — Use Canary to securely conduct contactless check-in and process credit card authorizations, contracts, and amenities online. Canary is the only PCI Level-1 Compliant solution for hotel authorizations. Schedule a demo today, and see how we can help your properties reduce chargebacks, save time, and improve the guest experience.
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Series B, Seed
- United States, India, United Kingdom
Portfolio highlights
- Eden — Developer of non-invasive health technology designed to democratize access to early cancer risk assessment.
- Aven — Inventing new ways to save people money
- Cartwheel — Cartwheel is a powerful text-to-animation platform. Animate characters for your video, game, movie, ad, Social or VR project simply by typing.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, China
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- MBX Biosciences — Homepage - MBX Biosciences
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United States, Canada
Portfolio highlights
- Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
- KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
- Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- Nagish — Nagish captions your phone calls and empowers you to talk using text or voice. It's fast, private, and free.
- Aim Security — Aim is the industry guide to secure GenAI adoption, empowering security leaders to drive business productivity while ensuring proactive protection for all GenAI use cases.
- Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Lekko — Dynamically configure your software without redeployments. With Lekko, engineers can focus on executing and safely hand off daily reconfigurations.
- Perchwell — Real estate data visualization, analytics, market insights. Search Manhattan, Brooklyn, NYC, apartments, condos, co-ops, townhouses, homes for sale.
- Applied Intuition — Applied Intuition enables engineering and product development teams to safely develop, test, and deploy autonomous vehicles at scale.
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- InduPro — InduPro is a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies.
- Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- Conduce Health — Conduce Health is a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations.
- DeepLook Medical — Enhancing Medical Imaging with Revolutionary Software: DeepLook Medical envisions a future where data-driven imaging enables accurate, efficient, and personalized care across the entire treatment pathway.
- Manifest Technologies — Manifest Technologies was founded by a group of leading experts in computational neuroimaging and psychiatry at Yale University's School of Medicine. Our goal is to transform therapeutic development, diagnosis and treatment for CNS disorders. The company is advancing the world's first AI-powered computational neuroimaging system that quantifies neural and symptom data to create and choose the right therapy for the right patient at the right time.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- Applied Intuition — Applied Intuition enables engineering and product development teams to safely develop, test, and deploy autonomous vehicles at scale.
- Black Forest Labs — Black Forest Labs creates advanced generative deep learning models for images and videos. They focus on making these technologies widely accessible and transparent, ensuring that their innovations are easy to use and understand. This approach aims to democratize access to cutting-edge technology and foster greater trust and utility.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
- Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Post-IPO Equity
- United States, Canada, Ireland
Portfolio highlights
- Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
- Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
- New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- ZwitterCo — ZwitterCo is revolutionizing water & wastewater treatment with cutting-edge membrane technology, along with providing sustainable, high-efficiency solutions.
- Odyssey — Hollywood-grade visual AI.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
- Myeloid Therapeutics — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
- Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.
- Molten Industries — Decarbonizing the world's chemical and heavy industries
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Canada
Portfolio highlights
- Harvey — Harvey builds custom LLMs for elite law firms to tackle the most complex legal challenges across every practice area, jurisdiction and legal system in the world.
- Altana — Connect to the only dynamic, intelligent, universal map of the global supply chain.
- Again — SecondCircle makes carbon negative chemicals for a cleaner future. We are the first carbon negative chemical manufacturer that can scale to meet global demand. The best thing about it: we use carbon dioxide as a feedstock.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, France, Switzerland
Portfolio highlights
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
- Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Seed, Series B
- United States, Austria, Israel
Portfolio highlights
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
- Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Switzerland
Portfolio highlights
- Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
- Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
- Biotechnology, Health Care, Medical Device
- Angel, Seed, Series A
- United States, Canada, India
Portfolio highlights
- Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
- Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
- Biotechnology, Health Care, Life Science
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
- SeLux Diagnostics — SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
- Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Canada, United Kingdom
Portfolio highlights
- Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
- Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
- Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Seed, Series A
- United States, Israel, The Netherlands
Portfolio highlights
- Neurava — Neurava has developed wearable diagnostics for epilepsy patients including those at risk of SUDEP. The company specializes in the fields of medical device manufacturing, healthcare, and health diagnostics.
- InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
- Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.
Show more
Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Kudos — Kudos is a retail company that offers natural disposable baby diapers with cotton liners. The company's chemical-free diapers are made of plant-based renewable materials, providing parents with natural diapers that suit babies' sensitive skin. It was founded by Amrita Saigal in 2019 and is headquartered in Boston, Massachusetts, USA.
- teachme.to — Teachme.to is a community of learners discovering lessons for everything.
- Savvy Wealth — Savvy is the next-generation wealth management firm that pairs world-class advisors with modern software to help clients achieve their financial goals.
INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH
INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Canada, Estonia
Portfolio highlights
- Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
- Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
- Fractyl Health — Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly
The North Carolina Biotechnology Center is a private, non-profit corporation funded by the N.C. General Assembly to strengthen biotechnology research, business and education statewide. The Center is not a site for laboratory research; it works to support job creation in the biotechnology industry.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Debt Financing, Grant, Funding Round
- United States, United Kingdom
Portfolio highlights
- Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
- QATCH Technologies — Get the most out of a drop
- Atlantic Fish Company — Atlantic Fish Co is a cultivated seafood company using cellular agriculture to bring the world sustainable delicious seafood.
Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Seed, Series A, Series B
- United States, United Kingdom, New Zealand
Portfolio highlights
- Astranis — Four billion people still have no internet access. Astranis is here to change that. We're making small satellites for geostationary orbit, recently signed a contract to triple the satellite internet capacity of Alaska, and raised our Series A from Andreessen Horowitz.
- Hyfé — Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers.
- Macro Oceans — Transforming seaweed into low-carbon chemicals for materials, food, cosmetics and more
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Funding Round
- United States, United Kingdom, Israel
Portfolio highlights
- OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
- Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
Wisconsin Investment Partners is an Angel Investment Group in Madison, Wisconsin founded in 2000 with 20 members. Membership has grown to 50+ members in recent years, bringing significant knowledge and experience.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Funding Round, Seed, Series A
- United States, Canada, United Kingdom
Portfolio highlights
- Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
- BeeReaders — ## Build Setup
- Midwest Games — Midwest Games is a video game publisher focused on creating opportunities for the abundant talent across the Midwest and other underrepresented regions.
Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series C, Series A
- United States, China, United Kingdom
Portfolio highlights
- Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
- Unicycive Therapeutics — Unicycive Therapeutics (UNCY) invents and develop medications that make a meaningful difference in the lives of kidney patients and their caregivers.
- Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, United Kingdom, China
Portfolio highlights
- Transcarent — The One Place for Health and Care
- Edgewood Oncology — We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients. We look forward to further developing this compound using a precision medicine approach in patient population
- Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, France, China
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, Canada, Denmark
Portfolio highlights
- Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
- Bridge Medicines — MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the
- Sembiosys Genetics — SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.
Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.
Show more
Investment focus
- Software, Health Care, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- Igloo — Our mission is to create the largest onchain community, driving the consumer crypto revolution.
- Caldera — Deploy production-grade rollups on Caldera with Arbitrum Orbit or OP Stack. Caldera blockchains are live and production-ready. It takes under half an hour to deploy your Ethereum-compatible application to a Caldera Chain.
- Aven — Inventing new ways to save people money
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, Australia, United Kingdom
Portfolio highlights
- Colorescience — Know Better Skin with Colorescience. From mineral sunscreen to clinical skincare products, achieve a clear, even complexion and protect your skin from the damaging effects of the sun and environmental aggressors such as pollution. Shop Now!
- Leap Therapeutics — Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
- Proteostasis Therapeutics — Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
- Software, Health Care, Information Technology
- Seed, Series A, Funding Round
- United States, Germany
Portfolio highlights
- HubiFi — SaaS Financial Automation & Analysis for High Transaction Businesses
- Trace — Trace is the simplest way ever to create AR content and experiences for your product and business.
- Niobium Microsystems — Niobium Microsystems creates custom integrated circuit and microelectronic system solutions for clients with complex power, performance, and security constraints.
Investors by industry
Climate
Community
Gaming
Energy
FinTech
Impact
Biotech
Media (entertainment)
Hardware
Proptech
Marketplace
Artificial intelligence
Consumer
Health Care
EdTech
Sustainability
Agriculture (agtech)
Venture Capital
Photography
B2B
Medical
Social Network
Wellness
Android
Social Media
Digital Media
Google
Mobile
Franchise
Music
Sports
Facebook
Legal
eSports
Local
Construction
Email
Enterprise Software
Internet
Art
Manufacturing
Travel
Recruiting
Cannabis
Biotechnology
Fitness
Platforms
Hospitality
Mobile Advertising
Medical Device
Automotive
Wine And Spirits
Crowdfunding
Social
CleanTech
Transportation
Mobile Apps
InsurTech
Enterprise
Infrastructure
LGBT
Education
Food and Beverage
Payments
Video Games
Retail
Fashion
Finance
Publishing
Clean Energy
Financial Services
Big Data
Web3
Beauty
Oil and Gas
Real Estate
Organic Food
Theatre
Film
Life Science
Non Profit
Sporting Goods
Renewable Energy
SaaS
Celebrity
Restaurants
Social Impact
Software
Cryptocurrency
Blockchain
Investors by country
South Korea
New Zealand
Germany
Ireland
United States
Australia
India
United Kingdom
Canada
Japan
Vietnam
Sri Lanka
China
Saudi Arabia
Middle East
Africa
Oceania
Asia
Europe
Indonesia
Singapore
Spain
Armenia
LATAM
Brazil
Qatar
South Africa
Georgia
Bahrain
Belize
Ethiopia
Bermuda
Chile
Costa Rica
France
Estonia
Ghana
Denmark
Belarus
Czech Republic
Ecuador
Egypt
Croatia
Finland
Hong Kong
Kenya
Algeria
Mexico
Morocco
Gibraltar
Kazakhstan
Panama
Kuwait
Faroe Islands
Greece
Cayman Islands
Liberia
Malta
Jersey
Liechtenstein
Norway
Peru
Hungary
Israel
Malaysia
Mauritius
Barbados
Belgium
Lithuania
Mali
Philippines
Bulgaria
Nicaragua
Cambodia
Lebanon
Myanmar
Italy
Dominican Republic
Portugal
Thailand
Slovenia
Azerbaijan
Serbia
Sierra Leone
Rwanda
Poland
San Marino
Zimbabwe
Turkey
Seychelles
Bahamas
Tanzania
Sweden
Puerto Rico
Nigeria
Taiwan
Uruguay
Senegal
Venezuela
Namibia
El Salvador
Zambia
Iraq
Tunisia
Iceland
Uzbekistan
Uganda
United Arab Emirates
Russian Federation
Togo
Ukraine
Tajikistan
Honduras
Bolivia
Isle of Man
Luxembourg
Pakistan
Albania
Bangladesh
Argentina
Romania
Jordan
Grenada
Austria
Oman
Cyprus
Latvia
Switzerland
Cameroon
Guatemala
Colombia
Marshall Islands
Investors in United States by industry
FinTech
Enterprise
Health Care
Biotech
Consumer
Climate
EdTech
Marketplace
SaaS
Artificial intelligence
Community
Hardware
Gaming
Media (entertainment)
Restaurants
Venture Capital
Film
Retail
Video Games
B2B
LGBT
Financial Services
Education
Oil and Gas
Proptech
Cryptocurrency
Payments
Food and Beverage
Wine And Spirits
Organic Food
Crowdfunding
Medical
Internet
Wellness
Social Media
Email
Social Network
Celebrity
Manufacturing
Art
Music
Theatre
Android
Blockchain
Franchise
Construction
Legal
Google
Software
Local
Sports
eSports
Fitness
Hospitality
Automotive
InsurTech
CleanTech
Travel
Biotechnology
Cannabis
Mobile Advertising
Beauty
Platforms
Real Estate
Fashion
Social
Web3
Life Science
Photography
Sporting Goods
Clean Energy
Publishing
Renewable Energy
Recruiting
Mobile
Mobile Apps
Social Impact
Infrastructure
Sustainability
Finance
Non Profit
Impact
Enterprise Software
Digital Media
Transportation
Facebook
Big Data
Medical Device
Energy
Agriculture (agtech)